FK506 promotes functional recovery in crushed rat sciatic nerve

In this study we examine whether the systemic administration of FK506 or Cyclosporin A (CsA) expedited functional recovery following an axonotmetic nerve injury, and compared their effects in a rat model. Seventy‐five adult Buffalo rats received a crush injury to the right posterior tibial nerve and...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve 2000-04, Vol.23 (4), p.633-640
Main Authors: Lee, Michelle, Doolabh, Vaishali B., Mackinnon, Susan E., Jost, Sarah
Format: Article
Language:English
Subjects:
Analysis of Variance
Animals
axonotmetic injury
Biological and medical sciences
blood-nerve barrier
Cyclosporin A
Cyclosporine - pharmacology
FK506
Male
Medical sciences
Miscellaneous
Motor Activity - drug effects
Motor Activity - physiology
Nerve Crush
nerve regeneration
Neuropharmacology
Paralysis - pathology
Paralysis - physiopathology
Pharmacology. Drug treatments
Rats
Rats, Inbred BUF
Sciatic Nerve - drug effects
Sciatic Nerve - injuries
Sciatic Nerve - physiology
Tacrolimus - pharmacology
Tibial Nerve - drug effects
Tibial Nerve - injuries
Tibial Nerve - physiology
Time Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study we examine whether the systemic administration of FK506 or Cyclosporin A (CsA) expedited functional recovery following an axonotmetic nerve injury, and compared their effects in a rat model. Seventy‐five adult Buffalo rats received a crush injury to the right posterior tibial nerve and subsequently underwent either no treatment (group I), daily injections of FK506 (group II), or daily injections of CsA (group III). Walking track analysis demonstrated return of hindlimb function by 20 days postoperatively in group I, 14 days in group II, and 18 days in group III. The blood–nerve barrier (BNB) was reconstituted by postoperative day (POD) 7 in both FK506‐ and CsA‐treated animals and by POD 13 in control animals. These results suggest that recovery of function is more rapid with daily administration of FK506 than with CsA or no treatment, perhaps because of earlier restoration of the blood–nerve barrier. Agents that facilitate nerve regeneration have the potential to limit the extent of motor endplate loss and muscle atrophy seen with prolonged denervation, thereby limiting permanent functional loss. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 633–640, 2000.
ISSN:0148-639X
1097-4598
DOI:10.1002/(SICI)1097-4598(200004)23:4<633::AID-MUS24>3.0.CO;2-Q